🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and Vimy Pharma Are Redefining Affordable Care
By MedicinMan Editorial Team
Published on October 18, 2025 | Category: Global Health & Pharma | Tags: #Insulin #Biocon #Civica #CalRx #VimyPharma #AffordableCare #Biosimilars #HealthcareInnovation
🧬 A New Era for Affordable Insulin
In a landmark announcement this October, Biocon Biologics Ltd. (BBL) and Civica, Inc. unveiled an expanded partnership designed to transform insulin accessibility in the United States.
Under this multi-year distribution agreement, Biocon Biologics will manufacture Insulin Glargine, while Civica distributes it under its own private label, including California’s CalRx brand. The initiative promises to make high-quality insulin more affordable for the 38.4 million Americans living with diabetes.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
